HomeCompareMGTA vs EPRT

MGTA vs EPRT: Dividend Comparison 2026

MGTA yields 285.88% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGTA wins by $1097.34M in total portfolio value
10 years
MGTA
MGTA
● Live price
285.88%
Share price
$0.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1097.40M
Annual income
$650,077,392.84
Full MGTA calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — MGTA vs EPRT

📍 MGTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGTAEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGTA + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGTA pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGTA
Annual income on $10K today (after 15% tax)
$24,299.60/yr
After 10yr DRIP, annual income (after tax)
$552,565,783.91/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, MGTA beats the other by $552,554,588.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGTA + EPRT for your $10,000?

MGTA: 50%EPRT: 50%
100% EPRT50/50100% MGTA
Portfolio after 10yr
$548.73M
Annual income
$325,045,281.85/yr
Blended yield
59.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

MGTA
Analyst Ratings
4
Buy
6
Hold
Consensus: Hold
Altman Z
-0.4
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGTA buys
0
EPRT buys
0
No recent congressional trades found for MGTA or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGTAEPRT
Forward yield285.88%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1097.40M$64.3K
Annual income after 10y$650,077,392.84$13,170.85
Total dividends collected$1051.82M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: MGTA vs EPRT ($10,000, DRIP)

YearMGTA PortfolioMGTA Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$39,288$28,587.76$11,212$512.01+$28.1KMGTA
2$147,005$104,967.23$12,689$692.09+$134.3KMGTA
3$524,362$367,066.84$14,521$944.30+$509.8KMGTA
4$1,784,727$1,223,658.84$16,841$1,302.88+$1.77MMGTA
5$5,802,051$3,892,393.74$19,841$1,821.64+$5.78MMGTA
6$18,034,330$11,826,135.71$23,818$2,587.47+$18.01MMGTA
7$53,650,753$34,354,018.98$29,230$3,744.65+$53.62MMGTA
8$152,920,863$95,514,557.73$36,816$5,540.38+$152.88MMGTA
9$418,060,242$254,434,918.57$47,806$8,413.17+$418.01MMGTA
10$1,097,401,852$650,077,392.84$64,324$13,170.85+$1097.34MMGTA

MGTA vs EPRT: Complete Analysis 2026

MGTAStock

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full MGTA Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this MGTA vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGTA vs SCHDMGTA vs JEPIMGTA vs OMGTA vs KOMGTA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.